Exploiting APC function as a novel cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The Adenomatous Polyposis Coli (APC) tumor suppressor is frequently mutated in various epithelial cancers, including colorectal, breast, pancreatic, and lung cancers.
• APC mutations lead to a truncated protein, loss of function, and are implicated in early cancer development, marking APC as a critical gatekeeper.
• APC regulates numerous cellular functions beyond Wnt/β-catenin signaling, including polarity, microtubule dynamics, cell cycle, DNA repair, apoptosis, and migration.

Purpose of the Study:

• To review the normal functions of APC and their implications for cancer treatment.
• To discuss the role of APC loss in epithelial tumorigenesis.
• To provide an overview of therapeutic strategies targeting both Wnt-dependent and Wnt-independent functions of APC.

Main Methods:

• Literature review of studies on APC function, mutations, and therapeutic strategies.
• Analysis of APC's role in various epithelial cancers.
• Synthesis of current and emerging therapeutic approaches targeting APC.

Main Results:

• Loss of APC function contributes to cancer development and chemoresistance by disrupting normal cellular processes.
• APC's multifaceted roles offer multiple avenues for therapeutic intervention.
• Therapeutic strategies include APC reintroduction, targeting activated pathways, and inducing apoptosis in APC-mutant cells.

Conclusions:

• APC is a vital tumor suppressor with diverse cellular functions, making its loss a significant driver of cancer.
• Targeting APC's Wnt-dependent and -independent functions presents promising therapeutic opportunities for epithelial cancers.
• Restoring or compensating for APC loss is a key strategy for overcoming therapeutic resistance in APC-mutant cancers.